AYTU (Aytu BioPharma) Other Stockholders Equity: $0.00 Mil (As of Mar. 2026)


AYTU Aytu BioPharma Inc AYTU
40 GF Score
Price $2.17
GF Value $0.85
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Aytu BioPharma Other Stockholders Equity?

Aytu BioPharma AYTU -0.56% 40 Other Stockholders Equity is $0.00 Mil as of Mar. 2026. GuruFocus rates AYTU with a GF Score™ of 40/100 and a GF Value™ of $0.85 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Aytu BioPharma's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $0.00 Mil.

Aytu BioPharma's quarterly Other Stockholders Equity increased from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.00 Mil) but then declined from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

Aytu BioPharma's annual Other Stockholders Equity increased from Jun. 2023 ($0.00 Mil) to Jun. 2024 ($0.00 Mil) but then stayed the same from Jun. 2024 ($0.00 Mil) to Jun. 2025 ($0.00 Mil).

Aytu BioPharma Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Aytu BioPharma's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aytu BioPharma Other Stockholders Equity Chart

Aytu BioPharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.00 0.00 0.00 0.00

Aytu BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
AYTU
40GF Score
Aytu BioPharma Inc AYTU
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aytu BioPharma Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.00 Mil mean?
Aytu BioPharma (AYTU) has a Other Stockholders Equity of $0.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Aytu BioPharma and its competitors.
Is Aytu BioPharma's Other Stockholders Equity too high?
Aytu BioPharma's current Other Stockholders Equity is $0.00 Mil. Overall, Aytu BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aytu BioPharma's Other Stockholders Equity compare to TXMD and CPHI?
Aytu BioPharma's Other Stockholders Equity of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Aytu BioPharma and its competitors. Aytu BioPharma's current Other Stockholders Equity is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aytu BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Aytu BioPharma (AYTU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.85, compared to a current price of $2.17 — trading 155% above its estimated fair value. The current Other Stockholders Equity is $0.00 Mil. Aytu BioPharma's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Aytu BioPharma (AYTU), the current Other Stockholders Equity is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aytu BioPharma (AYTU) Overvalued in 2026?

Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued. The current stock price of $2.17 is trading 155% above its estimated GF Value™ of $0.85. GuruFocus considers Aytu BioPharma to be Significantly Overvalued.

Key valuation signals for AYTU:

  • Other Stockholders Equity: $0.00 Mil
  • GF Value™: $0.85 vs. price of $2.17 (155% above fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the AYTU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aytu BioPharma Business Description

Address 7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
40GF Score

Get the complete analysis for AYTU

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.17
Price
$0.85
GF Value